Osteoarthritis Drugs Market Share, Analysis and Forecast 2034
Global Osteoarthritis Drugs Market Growth, Size, Trends Analysis - By Drug Type, By Route of Administration, By Anatomy, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jul-2025 | Report ID: HLCA25220 | Pages: 1 - 222 | Formats*: |
| Category : Healthcare | |||
Global Osteoarthritis Drugs Market Introduction and Overview
According to SPER Market Research, the Global Osteoarthritis Drugs Market is estimated to reach USD 18.98 billion by 2034 with a CAGR of 7.13%.
The report includes an in-depth analysis of the Global Osteoarthritis Drugs Market, including market size and trends, product mix, Applications, and supplier analysis. The Osteoarthritis Drugs market was valued at USD 9.53 billion in 2024 and expanded at a CAGR of 7.13% during the analysis period. The sector is witnessing rapid expansion as a result of factors such as the rising prevalence of osteoarthritis, particularly among the elderly, and increased research and development activities for osteoarthritis therapies. As a result, advancements in osteoarthritis therapy and drug research, the launch of personalised osteoarthritis new drugs, and increased accessibility of therapies across various healthcare facilities are expected to drive market expansion.
By Drug Type Insights
Analgesics, corticosteroids, nonsteroidal anti-inflammatory drugs, and visco supplementation agents are the five drug type that make up the global market. In 2024, the Visco supplementation agents medication type segment dominated the market.
These medicines, composed of hyaluronic acid, lubricate and cushion the afflicted joints, reducing discomfort and enhancing mobility. They also provide a minimally invasive therapeutic alternative to people with mild to moderate osteoarthritis who haven't reacted well to conventional therapies.
By Route of Administration Insights
The osteoarthritis medications market is divided into three segments based on route of administration: oral, parenteral, and topical. The parenteral segment had the largest market share in 2024.
The segmental rise is due to variables such as improved pharmacokinetics and pharmacodynamics, efficacy for certain therapy, and convenience of administration.
Furthermore, parenteral administration routes provide a realistic option for giving osteoarthritis medications to older individuals who may have difficulties swallowing pills or have gastrointestinal problems. Therefore, one of the main demographic factors driving the need for parenteral administration routes in the treatment of osteoarthritis is the growing older population.
By Anatomy Insights
The osteoarthritis drug market is classified into five categories depending on anatomy: ankle osteoarthritis, hip osteoarthritis, knee osteoarthritis, shoulder osteoarthritis, and others.The knee osteoarthritis category is predicted to generate the most revenue over the projection period. Increased awareness of knee osteoarthritis, rising prevalence of knee osteoarthritis, and an aging population are all major drivers driving segmental growth.
By Distribution Channel Insights
Three distribution channels make up the market: online pharmacies, retail pharmacies, and hospital pharmacies. The segment with the highest CAGR during the projection period was hospital pharmacies.
Hospital chemists and orthopaedic doctors are expanding their involvement in delivering drug therapy management services to osteoarthritis patients. Medication counselling, adherence monitoring, dosage modifications, and therapy interventions may all be used to improve treatment outcomes and reduce side effects, thereby improving patient care and satisfaction.
Regional Insights
North America commanded a sizable market share in 2024 and is likely to dominate throughout the projection period. Factors such as rising osteoarthritis prevalence, favourable government regulations, and product introductions in the region are projected to considerably contribute to the market's growth over the forecast period. Furthermore, the aging population in North America is increasing, resulting in an increased prevalence of osteoarthritis disease. This demographic trend, together with the existence of important players in the market, is driving product demand and augmenting regional market growth.
Market Competitive Landscape
The osteoarthritis medications sector has a competitive landscape with established companies striving for market share. Key players are strengthening their product portfolios through strategic activities such as mergers, acquisitions, and alliances. The companies are actively pursuing a multifaceted approach to meet the growing need for effective osteoarthritis medications.
Recent Developments:
In March 2023, Remedium Bio, a biotech startup in the United States, and Exothera, a Belgian Contract Development and Manufacturing Organisation (CDMO), announced a strategic partnership to pursue AAV2-FGF18, a disease-modifying gene therapy for osteoarthritis. This collaboration intends to pool their skills and resources in order to develop and expand the market presence of this new therapy.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Connectivity, By Mounting |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Canadian Solar, CHINT Group, First Solar, JA SOLAR Technology Co., Ltd, JinkoSolar, LG Electronics, Shunfeng International Clean Energy Co., Ltd, The Solaria Corporation, Trina Solar. |
Key Topics Covered in the Report
- Global Osteoarthritis Drugs Market Size (FY’2021-FY’2034)
- Overview of Global Osteoarthritis Drugs Market
- Segmentation of Global Osteoarthritis Drugs Market By Drug Type (Visco Supplementation Agents, NSAIDs, Analgesics, Corticosteroids)
- Segmentation of Global Osteoarthritis Drugs Market By Route of Administration (Oral, Parenteral, Topical)
- Segmentation of Global Osteoarthritis Drugs Market By Anatomy (Ankle Osteoarthritis, Hip Osteoarthritis, Knee Osteoarthritis, Shoulder Osteoarthritis, Other Anatomies)
- Segmentation of Global Osteoarthritis Drugs Market By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacy)
- Statistical Snap of Global Osteoarthritis Drugs Market
- Expansion Analysis of Global Osteoarthritis Drugs Market
- Problems and Obstacles in Global Osteoarthritis Drugs Market
- Competitive Landscape in the Global Osteoarthritis Drugs Market
- Details on Current Investment in Global Osteoarthritis Drugs Market
- Competitive Analysis of Global Osteoarthritis Drugs Market
- Prominent Players in the Global Osteoarthritis Drugs Market
- SWOT Analysis of Global Osteoarthritis Drugs Market
- Global Osteoarthritis Drugs Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape
5.3.PORTERs Five Forces
5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry
5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Osteoarthritis Drugs Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Osteoarthritis Drugs Market
7.Global Osteoarthritis Drugs Market, By Drug Type (USD Million) 2021-2034
7.1.Visco Supplementation Agents7.2.Nonsteroidal Anti-Inflammatory Drugs
7.2.1.Naproxen7.2.2.Aspirin7.2.3.Diclofenac7.2.4.Ibuprofen7.2.5.Celecoxib7.2.6.Meloxicam7.2.7.Piroxicam7.2.8.Ketoprofen7.2.9.Other NSAIDs
7.3.Analgesics
7.3.1.Duloxetine7.3.2.Acetaminophen
7.4.Corticosteroids7.5.Other Drug Types
8.Global Osteoarthritis Drugs Market, By Route of Administration (USD Million) 2021-2034
8.1.Oral8.2.Parenteral8.3.Topical
9.Global Osteoarthritis Drugs Market, By Anatomy (USD Million) 2021-2034
9.1.Ankle Osteoarthritis9.2.Hip Osteoarthritis9.3.Knee Osteoarthritis9.4.Shoulder Osteoarthritis9.5.Other Anatomies
10.Global Osteoarthritis Drugs Market, By Distribution Channel (USD Million) 2021-2034
10.1.Hospital Pharmacies10.2.Retail Pharmacies10.3.Online Pharmacy
11.Global Osteoarthritis Drugs Market, (USD Million) 2021-2034
11.1.Global Osteoarthritis Drugs Market Size and Market Share
12.Global Osteoarthritis Drugs Market, By Region, (USD Million) 2021-2034
12.1.Asia-Pacific
12.1.1.Australia12.1.2.China12.1.3.India12.1.4.Japan12.1.5.South Korea12.1.6.Rest of Asia-Pacific
12.2.Europe
12.2.1.France12.2.2.Germany12.2.3.Italy12.2.4.Spain12.2.5.United Kingdom12.2.6.Rest of Europe
12.3.Middle East and Africa
12.3.1.Kingdom of Saudi Arabia12.3.2.United Arab Emirates12.3.3.Qatar12.3.4.South Africa12.3.5.Egypt12.3.6.Morocco12.3.7.Nigeria12.3.8.Rest of Middle-East and Africa
12.4.North America
12.4.1.Canada12.4.2.Mexico12.4.3.United States
12.5.Latin America
12.5.1.Argentina12.5.2.Brazil12.5.3.Rest of Latin America
13.Company Profile
13.1.Anika Therapeutics
13.1.1.Company details13.1.2.Financial outlook13.1.3.Product summary13.1.4.Recent developments
13.2.Assertio Holdings, Inc
13.2.1.Company details13.2.2.Financial outlook13.2.3.Product summary13.2.4.Recent developments
13.3.Bayer AG
13.3.1.Company details13.3.2.Financial outlook13.3.3.Product summary13.3.4.Recent developments
13.4.Bioventus
13.4.1.Company details13.4.2.Financial outlook13.4.3.Product summary13.4.4.Recent developments
13.5.Ferring Pharmaceuticals Inc
13.5.1.Company details13.5.2.Financial outlook13.5.3.Product summary13.5.4.Recent developments
13.6.GlaxoSmithKline plc
13.6.1.Company details13.6.2.Financial outlook13.6.3.Product summary13.6.4.Recent developments
13.7.Novartis AG
13.7.1.Company details13.7.2.Financial outlook13.7.3.Product summary13.7.4.Recent developments
13.8.Pacira Pharmaceuticals, Inc
13.8.1.Company details13.8.2.Financial outlook13.8.3.Product summary13.8.4.Recent developments
13.9.Pfizer Inc
13.9.1.Company details13.9.2.Financial outlook13.9.3.Product summary13.9.4.Recent developments
13.10.Sanofi SA
13.10.1.Company details13.10.2.Financial outlook13.10.3.Product summary13.10.4.Recent developments
13.11.Others
14.Conclusion
15.List of Abbreviations
16.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
You can get the sample pages by clicking the link - Click Here
Osteoarthritis Drugs Market size is USD 18.98 billion from 2025 to 2034.
Osteoarthritis Drugs Market is covered By Drug Type, By Route of Administration, By Anatomy, By Distribution Channel
The North America is anticipated to have the highest Market share in the Osteoarthritis Drugs Market.
Anika Therapeutics, Assertio Holdings, Inc, Bayer AG, Bioventus, Ferring Pharmaceuticals Inc, GlaxoSmithKline plc, Novartis AG, Pacira Pharmaceuticals, Inc, Pfizer Inc, Sanofi SA.
The report includes an in-depth analysis of the Global Osteoarthritis Drugs Market, including market size and trends, product mix, Applications, and supplier analysis.
Osteoarthritis Drugs Market is projected to reach USD 18.98 billion by 2034, growing at a CAGR of of 7.13% during the forecast period.
Osteoarthritis Drugs Market grew in Market size from 2025. The Market is expected to reach USD 18.98 billion by 2034, at a CAGR of 7.13% during the forecast period.
Osteoarthritis Drugs Market CAGR of 7.13% during the forecast period.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
